Cancer Genetics' Proprietary FHACT Test For Cervical Cancer Gets CE Marking

(RTTNews) - Cancer Genetics, Inc. (CGIX) Tuesday said its proprietary DNA-probe based test for cervical cancer or FHACT has received the CE Marking. As a result FHACT test can be carried out freely within the European Economic Area , which includes the 28 member states of the EU as well as the European Free Trade Association.

The Conformité Européenne mark or CE mark is a conformity mark which enables the company to market its vitro diagnostic medical devices in the European Economic Area. The marking indicates the test's compliance with European Union product safety legislation.

The company said its proprietary FHACT test can identify those women most at risk for cervical disease and can also help reduce unnecessary, invasive testing and over-treatment in women who do not show the genomic abnormalities associated with disease progression.